HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis
Alexius Ramcharan(Leiden University Medical Center), Carine J.M. Doggen(Rijnstate Hospital), Frits R. Rosendaal(Leiden University Medical Center), Karlijn J. van Stralen(Amsterdam UMC Location University of Amsterdam), Aukje K. Mantel‐Teeuwisse(Utrecht University), Jaapjan D. Snoep(Leiden University Medical Center)
Cited by 101
Related Papers
Incidence and mortality of venous thrombosis: a population‐based study
|Journal of Thrombosis and Haemostasis|2007|1.4k
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
|The Lancet|2011|1.3k
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
|The Lancet|1994|1.1k
Hyperhomocysteinemia as a Risk Factor for Deep-Vein Thrombosis
|New England Journal of Medicine|1996|1.1k